Correlation Between Neuropace and Sight Sciences
Can any of the company-specific risk be diversified away by investing in both Neuropace and Sight Sciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Sight Sciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neuropace and Sight Sciences, you can compare the effects of market volatilities on Neuropace and Sight Sciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Sight Sciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Sight Sciences.
Diversification Opportunities for Neuropace and Sight Sciences
-0.54 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Neuropace and Sight is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Sight Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sight Sciences and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Sight Sciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sight Sciences has no effect on the direction of Neuropace i.e., Neuropace and Sight Sciences go up and down completely randomly.
Pair Corralation between Neuropace and Sight Sciences
Given the investment horizon of 90 days Neuropace is expected to generate 1.33 times more return on investment than Sight Sciences. However, Neuropace is 1.33 times more volatile than Sight Sciences. It trades about 0.1 of its potential returns per unit of risk. Sight Sciences is currently generating about -0.19 per unit of risk. If you would invest 792.00 in Neuropace on August 30, 2024 and sell it today you would earn a total of 233.00 from holding Neuropace or generate 29.42% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Neuropace vs. Sight Sciences
Performance |
Timeline |
Neuropace |
Sight Sciences |
Neuropace and Sight Sciences Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Neuropace and Sight Sciences
The main advantage of trading using opposite Neuropace and Sight Sciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Sight Sciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sight Sciences will offset losses from the drop in Sight Sciences' long position.Neuropace vs. Electromed | Neuropace vs. Orthopediatrics Corp | Neuropace vs. SurModics | Neuropace vs. Paragon 28 |
Sight Sciences vs. Si Bone | Sight Sciences vs. Rapid Micro Biosystems | Sight Sciences vs. Tactile Systems Technology | Sight Sciences vs. Pulmonx Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Complementary Tools
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |